

CLAIM AMENDMENTS

1 through 9 (canceled).

- 1 10. (New) A compound selected from the group consisting
2 of
3 (a) Leu Lys Ala Thr Thr Asn Ser Lys Leu Met Met Tyr (Seq ID NO: 1);
4 (b) Val Asp Met Ile Asn Asp Val Gln Pro Leu Thr Pro (Seq ID NO: 2);
5 (c) Val Asp Met Ile Asp Asp Val Gln Pro Leu Thr Pro (Seq ID NO: 3);
6 (d) Val Asp Met Ile Asn Asp Val Gln Pro Met Thr Pro (Seq ID NO: 4);
7 (e) Val Tyr Met Met Asn Asn Gly Gln Pro Pro Ser Pro (Seq ID NO: 5);
8 (f) Val Asp Met Ile Asn Asp Val Gln Pro Met Ser Pro (Seq ID NO: 6);
9 (g) Trp His Trp Gln Trp Thr Pro Trp Ser Ile Gln Pro (Seq ID NO: 7);
10 (h) His Ser Pro Leu Asp Ser Ser Arg His Ala Thr Tyr (Seq ID NO: 8);
11 (i) His Tyr Thr Leu Asp Ser Cys Arg His Pro Thr Tyr (Seq ID NO: 9);
12 (j) Val Tyr Ser Ser Thr Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 10);
13 (k) Val Tyr Ser Ser Asn Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 11);
14 (l) Val Tyr Ser Ser Asn Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 12);
15 (m) Val Tyr Leu Leu Asn Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 13);
16 (n) Val Tyr Leu Leu Ser Thr Arg Pro Leu Pro Ser Pro (Seq ID NO: 14);
17 (o) Val Tyr Trp Pro Thr Asn Arg Pro Leu Pro Ser Pro (Seq ID NO: 15);
18 (p) Val Gln Pro Ser Ile Asn Arn Pro His Gln Arg Pro (Seq ID NO: 16);
19 (q) Tyr His Asn Tyr Thr Thr Ala Pro His Ser Pro Ser (Seq ID NO: 17);
20 (r) Lys Pro Val Ile Ser Pro Thr Asn Ala Leu Gln Pro (Seq ID NO: 18);
21 (s) Val Thr Gly Pro Thr Lys Asn Leu Pro Ala Thr Thr (Seq ID NO: 19);
22 (t) Ala Ser His Val Asp Tyr Arg Arg Phe Leu Leu Thr (Seq ID NO: 20);
23 (u) Asp Gln Asp Phe Als Pro Asp Arg His Tyr Arg Leu (Seq ID NO: 21);
24 (v) Gln Lys Trp Pro Glu Thr Tyr Pro Asp Leu Ser Phe (Seq ID NO: 22);

25 (w) Gly Asp Pro Val Pro Gln Thr Tyr Ser Ala Ala Gly (Seq ID NO: 23);
26 (x) Ala Val Ser Val Asn Thr Lys Ile Asp Thr Glu Ala (Seq ID NO: 24);
27 (y) Gln Pro Asn Tyr Thr Ser Leu Leu Tyr Gly Thr Glu (Seq ID NO: 25);
28 (z) Thr Gln Pro Pro Ile His His Tyr Gln Leu Pro Ala (Seq ID NO: 26);
29 and
30 (aa) Gly Trp Asp His Ile His Gly Val His Gln His Val (Seq ID NO:
31 27)).

1 11. (New) Leu Lys Ala Thr Thr Asn Ser Lys Leu Met Met Tyr
2 (Seq ID NO: 1) as defined in claim 10.

1 12. (New) Val Asp Met Ile Asn Asp Val Gln Pro Leu Thr Pro
2 (Seq ID NO: 2) as defined in claim 10.

1 13. (New) His Ser Pro Leu Asp Ser Ser Arg His Ala Thr Tyr
2 (Seq ID NO: 8) as defined in claim 10.

1 14. (New) Val Tyr Ser Ser Thr Thr Arg Pro Leu Pro Ser Pro
2 (Seq ID NO: 10) as defined in claim 10.

1 15. (New) A pharmaceutical composition for the treatment
2 of transmissible spongiform encephalopathy which comprises a
3 therapeutically effective amount of the compound defined in claim 1
4 together with a pharmaceutically acceptable inert carrier or
5 diluent.

1 16. (New) The pharmaceutical composition defined in claim
2 15 in solid, semiliquid or liquid form.

1 17. (New) The pharmaceutical composition defined in claim
2 15 in the form of an injection solution, drop, juice, syrup, spray,
3 suspension, granulate, tablet, pellet, transdermal therapeutic
4 system, capsule, plaster, suppository, salve, cream, lotion, gel,
5 emulsion or aerosol form.

1 18. (New) The pharmaceutical composition defined in claim
2 15 further comprising an auxiliary substance selected from the group
3 consisting of a surface active substance, a coloring agent, a
4 preservative, a bursting agent, a smoothing agent, a lubricant, an
5 aromatizing agent and/or a binder.

1 19. (New) The peptide defined in claim 10 substituted or
2 modified by at least one component selected from the group
3 consisting of sugar residues, glucoromic acid, sulfate residues,
4 serine, glycine or aspartate.

1 20. (New) A method of making a peptide as defined in
2 claim 10 in that a solid phase synthesis in a liquid phase is used.

1 21. (New) A method of making a peptide as defined in
2 claim 10 wherein the peptide is expressed by a nucleic acid coding
3 therefore.

1 22. (New) A method of inhibiting replication of a PrP^{Sc}
2 prion in a mammalian subject which comprises the step of
3 administering to said subject a therapeutically effective amount of
4 the compound defined in claim 10.

1 23. (New) The method of inhibiting replication of a PrP^{Sc}
2 prion in a mammalian subject defined in claim 22 wherein the
3 mammalian subject is a human.